Related Experiment Video
Updated: Jul 9, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
Off-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Diseases
Journal of Drugs in Dermatology : JDD
|December 5, 2023
Summary
Janus kinase (JAK) inhibitors like upadacitinib and tofacitinib show promise for treating severe inflammatory skin conditions. This case series highlights their successful off-label use in dermatomyositis, hidradenitis suppurativa, cutaneous lupus, and Crohn's disease.
Area of Science:
- Dermatology and Immunology
- Pharmacology of Janus Kinase (JAK) Inhibitors
Background:
- Dysregulated Janus kinase (JAK) pathways and cytokine signaling are implicated in inflammatory skin disorders.
- Oral JAK inhibitors (upadacitinib, tofacitinib, baricitinib) are FDA-approved for rheumatic conditions but show potential in dermatology.
- JAK inhibitors offer broad targeted mechanisms for recalcitrant immune-related dermatologic diseases.
Purpose of the Study:
- To evaluate the off-label efficacy of upadacitinib and tofacitinib in patients with treatment-resistant inflammatory cutaneous disorders.
- To present a case series demonstrating successful outcomes in dermatomyositis, hidradenitis suppurativa, cutaneous lupus, and cutaneous Crohn's disease.
Main Methods:
- Retrospective case series of 6 patients with inflammatory cutaneous conditions who failed conventional therapies.
- Treatment administered included off-label use of upadacitinib or tofacitinib.
- Clinical outcomes were assessed based on symptom improvement and disease flares.
Main Results:
- Upadacitinib or tofacitinib yielded positive clinical outcomes in 3 dermatomyositis cases, with no recurrence when upadacitinib was used.
- Upadacitinib showed reduced systemic flares and moderate improvement in cutaneous symptoms for treatment-resistant hidradenitis suppurativa.
- Upadacitinib decreased cutaneous symptoms in cutaneous Crohn's disease without new flares; tofacitinib achieved complete resolution in cutaneous lupus.
Conclusions:
- Upadacitinib and tofacitinib represent potential therapeutic options for patients with treatment-resistant inflammatory skin diseases.
- These JAK inhibitors demonstrated efficacy in managing severe cases of dermatomyositis, hidradenitis suppurativa, cutaneous lupus, and cutaneous Crohn's disease.
- Further large-scale studies are warranted to confirm the broader applicability of these findings.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
143
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
143
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
121
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
121
01:29Inflammatory Bowel Disease IV: Pharmacological Management
130
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
130
01:29Drugs for Treatment of Ulcerative Colitis in IBD
145
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145